Citable company snapshot
VERTEX PHARMACEUTICALS INC / MA's latest SEC-sourced 2026-03-31 period shows $2.99B in revenue and $1.03B in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $2.99B | $3.19B | -6.4% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $1.14B | $1.21B | -5.6% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $1.03B | $1.19B | -13.4% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $1.43B | $498.00M | +186.8% |
| Free Cash Flow (computed) | Mar 31, 2026 | $1.29B | $348.60M | +271.4% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed May 5, 2026; accession 0000875320-26-000173.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
